先天性巨细胞病毒感染新生儿自然听力演变的风险因素
这项多中心队列研究纳入387名未治疗先天性巨细胞病毒感染新生儿,随访至少4年,分析听力改善、恶化和迟发性听力损失的风险因素。结果显示90%的耳听力稳定,6.3%出现迟发性听力损失,出生时即有听力损失的耳中70.6%恶化;早产与听力改善相关(OR 12.80),孕早期感染与迟发性听力损失相关(OR 10.10)。
要点
- 未治疗先天性巨细胞病毒感染患儿中,90%的耳听力保持稳定,6.3%出现迟发性听力损失。
- 出生时即有听力损失的耳中,70.6%出现听力恶化,仅6.6%改善。
- 早产与听力改善相关(OR 12.80),孕早期感染与迟发性听力损失相关(OR 10.10)。
核心结论
- 研究结果支持对未治疗的先天性听力损失患儿进行持续听力学随访,因为多数患者出现听力恶化。
- 血清转化时机与迟发性听力损失风险相关。
- 这些发现有助于家长咨询、患者分层和随访。
- 未来研究应关注治疗效应、已确定风险因素的影响以及高风险患者中可能出现的新风险因素。
研究设计与样本
- 多中心队列研究,纳入比利时佛兰德斯巨细胞病毒登记库中6家二级和三级医院的患者。
- 纳入未治疗先天性巨细胞病毒感染且至少4年听力学随访的新生儿,排除有其他可能感音神经性听力损失原因的患者。
- 数据收集时间为2007年1月1日至2022年2月7日,分析时间为2022年9月26日至2023年1月16日。
- 共纳入387名儿童,其中205/385名(53.2%)为男性,113名(29.2%)为症状性感染,274名(70.8%)为无症状性感染。
主要发现
- 774只耳中701只(90%)听力稳定(正常听力或自出生起稳定的听力损失)。
- 683只耳中43只(6.3%)出现迟发性听力损失(出生时听力正常后出现听力损失)。
- 出生时即有听力损失的耳中,34只中24只(70.6%)听力恶化,91只中6只(6.6%)听力改善。
- 早产与听力改善几率较高相关(OR 12.80;95% CI 2.03-80.68)。
- 迟发性听力损失在孕早期感染中更常见(OR 10.10;95% CI 2.90-34.48);孕晚期血清转化的104只耳均未发生迟发性听力损失。
临床怎么用
- 研究结果支持对未治疗的先天性听力损失患儿进行持续听力学随访,因为多数患者出现听力恶化。
- 血清转化时机与迟发性听力损失风险相关,这些发现有助于家长咨询、患者分层和随访。
局限性
- 未来研究应关注治疗效应、已确定风险因素的影响以及高风险患者中可能出现的新风险因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Congenital cytomegalovirus (cCMV) is the major cause of congenital nonhereditary sensorineural hearing loss in children. Currently, criteria to identify infants at increased risk for unfavorable hearing outcome are lacking. OBJECTIVE: To identify risk factors associated with cCMV-related hearing improvement, hearing deterioration, and late-onset hearing loss. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study included patients from 6 secondary and tertiary hospitals enrolled in the Flemish CMV registry (Belgium). Newborns with untreated cCMV infection with at least 4-year audiological follow-up were included. Patients who presented with other possible causes of sensorineural hearing loss were excluded. Data were collected for 15 years (January 1, 2007, to February 7, 2022) and analyzed from September 26, 2022, to January 16, 2023. MAIN OUTCOMES AND MEASURES: Primary outcome was hearing evolution (per-ear analysis; described as stable hearing, improvement, or deterioration). The association of gestational characteristics, clinical findings, timing of seroconversion, viral load, and hearing status at birth with hearing evolution was investigated using effect sizes (Cramer V, odds ratio [OR], or Hedges g). RESULTS: Of the 387 children, 205 of 385 with nonmissing data were male (53.2%), 113 (29.2%) had a symptomatic infection, and 274 (70.8%) had an asymptomatic infection. Every child was 4 years or older at final hearing evaluation. A total of 701 of 774 ears (90%) showed stable hearing (normal hearing or stable hearing loss since birth) over time. Late-onset hearing loss (normal hearing at birth followed by hearing loss) was present in 43 of 683 ears (6.3%). Among children with hearing loss present at birth, 24 of 34 ears (70.6%) had hearing deterioration, and 6 of 91 ears (6.6%) had hearing improvement. Prematurity was associated with a higher chance of hearing improvement (OR, 12.80; 95% CI, 2.03-80.68). Late-onset hearing loss was more prevalent in a first trimester infection (OR, 10.10; 95% CI, 2.90-34.48). None of the 104 ears of children with a third trimester seroconversion developed late-onset hearing loss. CONCLUSIONS AND RELEVANCE: Findings of this cohort study support that ongoing audiological follow-up for untreated children with congenital hearing loss is important, as the majority of patients had hearing deterioration. The timing of seroconversion was associated with the risk of developing late-onset hearing loss. These insights can aid in parental counseling, patient stratification, and follow-up. Future research should focus on the effect of treatment, the influence of determined risk factors, and the study of eventual new risk factors in patients at high risk to develop hearing loss.
引用
- De Cuyper E, Acke F, Keymeulen A, et al. Risk Factors for Natural Hearing Evolution in Newborns With Congenital Cytomegalovirus Infection. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 37917050. doi:10.1001/jamaoto.2023.3507
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。